Multiple myeloma highlights from ASH 2019

Bookmark and Share
Published: 10 Dec 2019
Views: 568
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Prof Heinz Ludwig speaks to ecancer at the 2019 ASH meeting in Orlando about some of the multiple myeloma (MM) highlights from this year's conference.

One of the studies he mentions is about the use of bispecific T-cell engagers (BiTEs) in relapsed/refractory disease, which has shown high response rates and good tolerability in these patients.

Prof Ludwig also discusses advancements in CAR T-cell therapy including one study which used alpha secretase to enhance the expression of BCMA which achieved a 100 percent response rate.

He also outlines other significant studies that focused on the treatment of MM, particularly in the newly-diagnosed setting that were presented at this year's conference.